Last reviewed 2026-04-20 · How we verify

Elidin (DIMETHAZAN)

Phase 2 active Small molecule

Elidin (generic name: DIMETHAZAN) is a dimethazan drug. It is currently in Phase 2 development.

Elidin is thought to work by interacting with a specific target in the body, although its exact mechanism of action is not well understood.

Elidin, also known as Dimethazan, is a small molecule drug in the dimethazan class. Its target and exact mechanism of action are unknown, but it is not FDA-approved for any indications. The commercial status of Elidin is unclear, with no information available on its patent status or generic manufacturers. Further research is needed to understand its potential uses and safety considerations. As a result, Elidin is not a widely recognized or used medication.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DIMETHAZAN
Drug class	dimethazan
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Elidin is a key that fits into one of those locks. When it binds to the lock, it can affect how the cell works, but we don't know exactly how it does that yet. More research is needed to understand how Elidin interacts with cells and what effects it has on the body.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Elidin CI brief — competitive landscape report
Elidin updates RSS · CI watch RSS

Frequently asked questions about Elidin

What is Elidin?

Elidin (DIMETHAZAN) is a dimethazan drug.

How does Elidin work?

Elidin is thought to work by interacting with a specific target in the body, although its exact mechanism of action is not well understood.

What is the generic name of Elidin?

DIMETHAZAN is the generic (nonproprietary) name of Elidin.

What drug class is Elidin in?

Elidin belongs to the dimethazan class. See all dimethazan drugs at /class/dimethazan.

What development phase is Elidin in?

Elidin is in Phase 2.

Drug class: All dimethazan drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing